On International Clinical Trials Day, the UK’s MHRA unveiled a major shift: a consultation on using external control arms (ECAs) based on real-world data…
- EU and German Courts Clarify Rules on Rx Drug Discounts in latest DocMorris decisions
- Mitigating Risk in Life Sciences Acquisitions
- The EU restricts access of Chinese medical devices to the European market
- Germany’s implementation of the European Accessibility Act (EAA) – Are medical devices affected?
- Council Clears Path to Trilogue on Pharma Package with Reduced Market Protection and stepped up Access Obligations
- External Control Arms Based on Real World Data: MHRA Consultation Opens
- The EU AI Act and Medical Devices: Innovation or Insanity Ahead?Â
- New White House Executive Order to Establish “Most-Favored-Nation” Drug Pricing
AI as a medical device (AIaMD) in Europe is at a crossroads. As manufacturers grapple with compliance under two separate legal regimes – the…
New White House Executive Order to Establish “Most-Favored-Nation” Drug Pricing
On May 12, 2025, the White House issued a wide-reaching Executive Order (“EO”) titled “Delivering Most Favored Nation Prescription Drug Pricing to American Patients”…
Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…
On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…
In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…
The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…
As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…
As already well noted on this blog, on 26 April 2023 the European Commission published a set of…